Join Growin Stock Community!
Back to LLY.US Analysis
My Watchlist

Ticker

Value

empty

There is no following symbol in this watchlist.

ros-chart

LLY ROS

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

As of Q3'25, Eli Lilly's ROS (Return on Sales) stands at 41.1%, reflecting a strong profitability level in the most recent quarter reported. This latest figure marks a notable increase from the previous quarter (Q2'25), which recorded a ROS of 43.6%, indicating a slight decline but still maintaining robust margins. Analyzing the period from Q1'23 to Q3'25, the ROS trend has shown considerable volatility, with significant dips in Q3'23 (4.5%) and Q3'24 (13.9%), followed by strong recoveries in subsequent quarters. Overall, the data reveals a general upward trajectory in profitability, especially from Q4'23 onward, culminating in the recent high levels above 40% in 2025. This pattern suggests improving operational efficiency and margin expansion over the observed timeframe.